<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9234742" created="07/04/01" creator="Yumiko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9234742</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Opposite effects of the <term id="T1" lex="acute_promyelocytic_leukemia_PML-retinoic_acid_receptor_alpha" sem="Protein_molecule">acute promyelocytic leukemia PML-retinoic acid receptor alpha</term> (<term id="T2" lex="RAR_alpha" sem="Protein_molecule">RAR alpha</term>) and <term id="T3" lex="PLZF-RAR_alpha_fusion_protein" sem="Protein_molecule">PLZF-RAR alpha <term id="A1" sem="Protein_molecule">fusion proteins</term></term> on <term id="T4" lex="retinoic_acid_signalling" sem="Other"><term id="T5" lex="retinoic_acid" sem="Organic_compound_other">retinoic acid</term> signalling</term>.</sentence>
<event KT="Investigation" id="E1">
<type class="Regulation"/>
<theme idref="T4"/>
<cause idref="T1" idref1="A1"/>
<clue><clueType>Opposite effects</clueType> <linkCause>of</linkCause> the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins <linkTheme>on</linkTheme> retinoic acid signalling.</clue>
</event>
<event KT="Investigation" id="E2">
<type class="Regulation"/>
<theme idref="T4"/>
<cause idref="T3"/>
<clue><clueType>Opposite effects</clueType> <linkCause>of</linkCause> the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins <linkTheme>on</linkTheme> retinoic acid signalling.</clue>
</event>
<event KT="Other" id="E53">
<type class="Cell_communication"/>
<theme idref="T5"/>
<clue>Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid <clueType>signalling</clueType>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Fusion proteins involving the <term id="T6" lex="retinoic_acid" sem="Organic_compound_other">retinoic acid</term> <term id="T7" lex="receptor_alpha" sem="Protein_molecule">receptor alpha</term> (<term id="T8" lex="RAR_alpha" sem="Protein_molecule">RAR alpha</term>) and the <term id="T9" lex="PML" sem="Protein_molecule">PML</term> or <term id="T10" lex="PLZF_nuclear_protein" sem="Protein_molecule">PLZF nuclear protein</term> are the genetic markers of <term id="T11" lex="acute_promyelocytic_leukemia" sem="Other">acute promyelocytic leukemias</term> (<term id="T12" lex="APL" sem="Other">APLs</term>).</sentence>
<sentence id="S3"><term id="A4" sem="Other"><term id="T13" lex="APL" sem="Other">APLs</term> with</term> the <term id="T14" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> or the <term id="T16" lex="PLZF-RAR_alpha_fusion_protein" sem="Protein_molecule">PLZF-RAR alpha fusion protein</term> are phenotypically indistinguishable except that they differ in their sensitivity to <term id="T17" lex="retinoic_acid_(RA)-induced_differentiation" sem="Other"><term id="T18" lex="retinoic_acid" sem="Organic_compound_other">retinoic acid</term> (<term id="A2" sem="Organic_compound_other">RA</term>)-induced <term id="A3" sem="Other">differentiation</term></term>: <term id="A5" sem="Cell_natural"><term id="T19" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> blasts</term> are sensitive to <term id="T20" lex="RA" sem="Organic_compound_other">RA</term> and patients enter disease remission after <term id="T21" lex="RA_treatment" sem="Other"><term id="T22" lex="RA" sem="Organic_compound_other">RA</term> treatment</term>, while <term id="A6" sem="Multicellular_organism_natural">patients with <term id="T23" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term></term> do not.</sentence>
<event KT="Other" id="E3">
<type class="Positive_regulation"/>
<theme idref="A3"/>
<cause idref="A2"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-<clueType>induced</clueType> differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>NER T14 MOD</comment></event>
<event KT="Fact" id="E4">
<type/>
<theme idref="A4" idref1="T14"/>
<cause idref="A2"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in <corefTheme>their</corefTheme> <clueType>sensitivity</clueType> <linkCause>to</linkCause> retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>NER T15 MOD, SENSITIVITY</comment></event>
<event KT="Fact" id="E5">
<type/>
<theme idref="A4" idref1="T16"/>
<cause idref="A2"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in <corefTheme>their</corefTheme> <clueType>sensitivity</clueType> <linkCause>to</linkCause> retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>TPS A4, SENSITIVITY</comment></event>
<event KT="Fact" id="E6">
<type/>
<theme idref="A5"/>
<cause idref="T20"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are <clueType>sensitive</clueType> <linkCause>to</linkCause> RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>SENSITIVITY</comment></event>
<event KT="Method" id="E7">
<type class="Artificial_process"/>
<theme idref="T22"/>
<theme idref="A5"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA <clueType>treatment</clueType>, while patients with PLZF-RAR alpha do not.</clue>
</event>
<event KT="Fact" id="E8">
<type class="Negative_regulation"/>
<theme idref="T13"/>
<cause idref="E7"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter <corefTheme>disease</corefTheme> <clueType>remission</clueType> <linkCause>after</linkCause> RA treatment, while patients with PLZF-RAR alpha do not.</clue>
</event>
<event KT="Fact" assertion="non-exist" id="E80">
<type/>
<theme idref="A6"/>
<cause idref="T20"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are <clueType>sensitive</clueType> <linkCause>to</linkCause> RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>SENSITIVITY</comment></event>
<event KT="Method" Polarity="Negative" assertion="non-exist" id="E74">
<type class="Artificial_process"/>
<theme idref="T22"/>
<theme idref="A6"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA <clueType>treatment</clueType>, while patients with PLZF-RAR alpha <cluePolarity>do not</cluePolarity>.</clue>
</event>
<event KT="Other" Polarity="Negative" assertion="non-exist" id="E75">
<type class="Negative_regulation"/>
<theme idref="T13"/>
<cause idref="E74"/>
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter <corefTheme>disease</corefTheme> <clueType>remission</clueType> <linkCause>after</linkCause> RA treatment, while patients with PLZF-RAR alpha do <cluePolarity>not</cluePolarity>.</clue>
</event>
<sentence id="S4">We here report that (i) like <term id="T24" lex="PML-RAR_alpha_expression" sem="Other"><term id="T25" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> expression</term>, <term id="T26" lex="PLZF-RAR_alpha_expression" sem="Other"><term id="T27" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> expression</term> blocks terminal differentiation of <term id="T28" lex="hematopoietic_precursor_cell_line" sem="Cell_cultured">hematopoietic precursor cell lines</term> (<term id="T29" lex="U937" sem="Cell_cultured">U937</term> and <term id="T30" lex="HL-60" sem="Cell_cultured">HL-60</term>) in response to different stimuli (<term id="T31" lex="vitamin_D3" sem="Organic_compound_other">vitamin D3</term>, <term id="A101" sem="Peptide">transforming growth factor <term id="T32" lex="beta1" sem="Organic_compound_other">beta1</term></term>, and <term id="T33" lex="dimethyl_sulfoxide" sem="Organic_compound_other">dimethyl sulfoxide</term>); (ii) <term id="T34" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term>, but not <term id="T35" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term>, increases <term id="T36" lex="RA_sensitivity" sem="Other"><term id="A7" sem="Organic_compound_other">RA</term> sensitivity</term> of <term id="T37" lex="hematopoietic_precursor_cell" sem="Cell_natural">hematopoietic precursor cells</term> and restores <term id="T38" lex="RA_sensitivity" sem="Other"><term id="A8" sem="Organic_compound_other">RA</term> sensitivity</term> of <term id="T39" lex="RA-resistant_hematopoietic_cell" sem="Cell_natural"><term id="A9" sem="Organic_compound_other">RA</term>-resistant <term id="A10" sem="Cell_natural">hematopoietic cells</term></term>; (iii) <term id="T40" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> and <term id="T41" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> have similar <term id="T42" lex="RA" sem="Organic_compound_other">RA</term> binding affinities; and (iv) <term id="T43" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> enhances the <term id="T44" lex="RA" sem="Organic_compound_other">RA</term> response of <term id="T45" lex="RA_target_gene" sem="DNA_family_or_group"><term id="T46" lex="RA" sem="Organic_compound_other">RA</term> target genes</term> (those for <term id="T47" lex="RAR_beta" sem="Protein_molecule">RAR beta</term>, <term id="T48" lex="RAR_gamma" sem="Protein_molecule">RAR gamma</term>, and <term id="T49" lex="transglutaminase_type_II" sem="Protein_molecule">transglutaminase type II</term> [<term id="T50" lex="TGase" sem="Protein_molecule">TGase</term>]) in vivo, while <term id="T51" lex="PLZF-RAR_alpha_expression" sem="Other"><term id="T52" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> expression</term> has either no effect (<term id="T53" lex="RAR_beta" sem="Protein_molecule">RAR beta</term>) or an inhibitory activity (<term id="T54" lex="RAR_gamma" sem="Protein_molecule">RAR gamma</term> and <term id="T55" lex="type_II_TGase" sem="Protein_molecule">type II <term id="T56" lex="TGase" sem="Protein_molecule">TGase</term></term>).</sentence>
<event KT="Other" id="E9">
<type class="Gene_expression"/>
<theme idref="T25"/>
<clue>We here report that (i) like PML-RAR alpha <clueType>expression</clueType>, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E10">
<type class="Gene_expression"/>
<theme idref="T27"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha <clueType>expression</clueType> blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E11">
<type class="Cell_differentiation"/>
<theme idref="T29"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal <clueType>differentiation</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E12">
<type class="Cell_differentiation"/>
<theme idref="T30"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal <clueType>differentiation</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E13">
<type class="Regulation"/>
<theme idref="E11"/>
<cause idref="T31"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" id="E14">
<type class="Regulation"/>
<theme idref="E11"/>
<cause idref="A101"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" id="E15">
<type class="Regulation"/>
<theme idref="E11"/>
<cause idref="T33"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" id="E16">
<type class="Regulation"/>
<theme idref="E12"/>
<cause idref="T31"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" id="E17">
<type class="Regulation"/>
<theme idref="E12"/>
<cause idref="A101"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" id="E18">
<type class="Regulation"/>
<theme idref="E12"/>
<cause idref="T33"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Analysis" id="E19">
<type class="Negative_regulation"/>
<theme idref="E13"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E20">
<type class="Negative_regulation"/>
<theme idref="E13"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E21">
<type class="Negative_regulation"/>
<theme idref="E14"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E22">
<type class="Negative_regulation"/>
<theme idref="E14"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E23">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E24">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E25">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E26">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E27">
<type class="Negative_regulation"/>
<theme idref="E17"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E28">
<type class="Negative_regulation"/>
<theme idref="E17"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E29">
<type class="Negative_regulation"/>
<theme idref="E18"/>
<cause idref="E9"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E30">
<type class="Negative_regulation"/>
<theme idref="E18"/>
<cause idref="E10"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E31">
<type class="Regulation"/>
<theme idref="T37"/>
<cause idref="A7"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA <clueType>sensitivity</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>SENSITIVITY</comment></event>
<event KT="Analysis" id="E32">
<type class="Positive_regulation"/>
<theme idref="E31"/>
<cause idref="T34"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, <clueType>increases</clueType> RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E33">
<type class="Positive_regulation"/>
<theme idref="E31"/>
<cause idref="T35"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but <cluePolarity>not</cluePolarity> PLZF-RAR alpha, <clueType>increases</clueType> RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" assertion="non-exist" id="E34">
<type/>
<theme idref="A10"/>
<cause idref="A9"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-<clueType>resistant</clueType> hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>RESISTANCE</comment></event>
<event KT="Other" id="E35">
<type class="Regulation"/>
<theme idref="T39"/>
<cause idref="A8"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA <clueType>sensitivity</clueType> <linkTheme>of</linkTheme> RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>SENSITIVITY</comment></event>
<event KT="Analysis" assertion="non-exist" id="E36">
<type class="Regulation"/>
<theme idref="E35"/>
<cause idref="T34"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and <clueType>restores</clueType> RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E37">
<type class="Binding"/>
<theme idref="T40"/>
<theme idref="T42"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA <clueType>binding affinities</clueType>; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E38">
<type class="Binding"/>
<theme idref="T41"/>
<theme idref="T42"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA <clueType>binding affinities</clueType>; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E39">
<type class="Regulation"/>
<theme idref="T45"/>
<cause idref="T44"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA <clueType>response</clueType> <linkTheme>of</linkTheme> RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E40">
<type class="Positive_regulation"/>
<theme idref="E39"/>
<cause idref="T43"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha <clueType>enhances</clueType> the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Other" id="E41">
<type class="Gene_expression"/>
<theme idref="T52"/>
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha <clueType>expression</clueType> has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E42">
<type class="Regulation"/>
<theme idref="T53"/>
<cause idref="E41"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either <cluePolarity>no</cluePolarity> <clueType>effect</clueType> (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E43">
<type class="Negative_regulation"/>
<theme idref="T54"/>
<cause idref="E41"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an <clueType>inhibitory activity</clueType> (RAR gamma and type II TGase).</clue>
</event>
<event KT="Analysis" id="E44">
<type class="Negative_regulation"/>
<theme idref="T55"/>
<cause idref="E41"/>
<clue>We here <clueKT>report</clueKT> that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an <clueType>inhibitory activity</clueType> (RAR gamma and type II TGase).</clue>
</event>
<sentence id="S5">These data demonstrate that <term id="T57" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term> and <term id="T58" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> have similar (inhibitory) effects on <term id="T59" lex="RA-independent_differentiation" sem="Other"><term id="A11" sem="Organic_compound_other">RA</term>-independent <term id="A12" sem="Other">differentiation</term></term> and opposite (stimulatory or inhibitory) effects on <term id="T60" lex="RA-dependent_differentiation" sem="Other"><term id="T61" lex="RA" sem="Organic_compound_other">RA</term>-dependent <term id="A13" sem="Other">differentiation</term></term> and that they behave in vivo as <term id="T62" lex="RA-dependent_enhancer" sem="DNA_domain_or_region"><term id="T63" lex="RA" sem="Organic_compound_other">RA</term>-dependent enhancers</term> or inhibitors of <term id="T64" lex="RA-responsive_gene" sem="DNA_family_or_group"><term id="T65" lex="RA" sem="Organic_compound_other">RA</term>-responsive <term id="A14" sem="DNA_family_or_group">genes</term></term>, respectively.</sentence>
<event KT="Other" Polarity="Negative" assertion="non-exist" id="E45">
<type class="Positive_regulation"/>
<theme idref="A12"/>
<cause idref="A11"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-<clueType><cluePolarity>independent</cluePolarity></clueType> differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Analysis" id="E46">
<type class="Negative_regulation"/>
<theme idref="E45"/>
<cause idref="T57"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have <clueType>similar (inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Analysis" id="E47">
<type class="Negative_regulation"/>
<theme idref="E45"/>
<cause idref="T58"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have <clueType>similar (inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Other" id="E48">
<type class="Positive_regulation"/>
<theme idref="A13"/>
<cause idref="T61"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-<clueType>dependent</clueType> differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Analysis" id="E49">
<type class="Positive_regulation"/>
<theme idref="E48"/>
<cause idref="T57"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and <clueType>opposite (stimulatory or inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Analysis" id="E50">
<type class="Negative_regulation"/>
<theme idref="E48"/>
<cause idref="T58"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and <clueType>opposite (stimulatory or inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Other" id="E51">
<type class="Positive_regulation"/>
<cause idref="T57"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that <corefCause>they</corefCause> behave in vivo as RA-dependent <clueType>enhancers</clueType> or inhibitors of RA-responsive genes, respectively.</clue>
<comment>NO THEME</comment></event>
<event KT="Other" id="E52">
<type class="Positive_regulation"/>
<cause idref="T58"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that <corefCause>they</corefCause> behave in vivo as RA-dependent <clueType>enhancers</clueType> or inhibitors of RA-responsive genes, respectively.</clue>
<comment>NO THEME</comment></event>
<event KT="Analysis" id="E54">
<type class="Positive_regulation"/>
<theme idref="E51"/>
<cause idref="T63"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-<clueType>dependent</clueType> enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Analysis" id="E55">
<type class="Positive_regulation"/>
<theme idref="E52"/>
<cause idref="T63"/>
<clue>These data <clueKT>demonstrate</clueKT> that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-<clueType>dependent</clueType> enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event KT="Other" id="E56">
<type class="Regulation"/>
<theme idref="A14"/>
<cause idref="T65"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-<clueType>responsive</clueType> genes, respectively.</clue>
</event>
<event KT="Other" id="E57">
<type class="Negative_regulation"/>
<theme idref="E56"/>
<cause idref="T57"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or <clueType>inhibitors</clueType> <linkTheme>of</linkTheme> RA-responsive genes, respectively.</clue>
</event>
<event KT="Other" id="E58">
<type class="Negative_regulation"/>
<theme idref="E56"/>
<cause idref="T58"/>
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or <clueType>inhibitors</clueType> <linkTheme>of</linkTheme> RA-responsive genes, respectively.</clue>
</event>
<sentence id="S6">Their different activities on the <term id="T66" lex="RA_signalling_pathway" sem="Other"><term id="T67" lex="RA" sem="Organic_compound_other">RA</term> signalling pathway</term> might underlie the different responses of <term id="A16" sem="Other"><term id="T68" lex="PML-RAR_alpha" sem="Protein_molecule">PML-RAR alpha</term></term> and <term id="A17" sem="Other"><term id="T69" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term></term> <term id="T70" lex="APL" sem="Other">APLs</term> to <term id="T71" lex="RA_treatment" sem="Other"><term id="A15" sem="Organic_compound_other">RA</term> treatment</term>.</sentence>
<event KT="Other" id="E59">
<type class="Regulation"/>
<theme idref="T66"/>
<cause idref="T57"/>
<clue><corefCause>Their</corefCause> different <clueType>activities</clueType> <linkTheme>on</linkTheme> the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA treatment.</clue>
</event>
<event KT="Other" id="E60">
<type class="Regulation"/>
<theme idref="T66"/>
<cause idref="T58"/>
<clue><corefCause>Their</corefCause> different <clueType>activities</clueType> <linkTheme>on</linkTheme> the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA treatment.</clue>
</event>
<event KT="Method" id="E61">
<type class="Artificial_process"/>
<theme idref="A15"/>
<clue>Their different activities on the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA <clueType>treatment</clueType>.</clue>
</event>
<event CL="L1" KT="Analysis" id="E62">
<type class="Regulation"/>
<theme idref="A16" idref1="T70"/>
<cause idref="E61"/>
<clue>Their different activities on the RA signalling pathway <clueKT><clueCL>might</clueCL></clueKT> underlie the different <clueType>responses</clueType> <linkTheme>of</linkTheme> PML-RAR alpha and PLZF-RAR alpha APLs <linkCause>to</linkCause> RA treatment.</clue>
</event>
<event CL="L1" KT="Analysis" id="E63">
<type class="Regulation"/>
<theme idref="A17" idref1="T70"/>
<cause idref="E61"/>
<clue>Their different activities on the RA signalling pathway <clueKT><clueCL>might</clueCL></clueKT> underlie the different <clueType>responses</clueType> <linkTheme>of</linkTheme> PML-RAR alpha and PLZF-RAR alpha APLs <linkCause>to</linkCause> RA treatment.</clue>
</event>
<sentence id="S7">The <term id="T72" lex="PLZF-RAR_alpha_fusion_protein" sem="Protein_molecule"><term id="T73" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> fusion protein</term> contains an approximately <term id="T74" lex="120-amino-acid_N-terminal_motif" sem="Protein_domain_or_region">120-amino-acid N-terminal motif</term> (called the <term id="T75" lex="POZ_domain" sem="Protein_domain_or_region">POZ domain</term>), which is also found in a variety of zinc finger proteins and a group of <term id="T76" lex="poxvirus_protein" sem="Protein_family_or_group"><term id="T77" lex="poxvirus" sem="Virus">poxvirus</term> proteins</term> and which mediates <term id="T78" lex="protein-protein_interaction" sem="Other">protein-protein interactions</term>.</sentence>
<event KT="Other" id="E64">
<type class="Correlation"/>
<theme idref="T57"/>
<theme idref="T58"/>
<clue>The PLZF-RAR alpha fusion protein contains an approximately 120-amino-acid N-terminal motif (called the POZ domain), which is also found in a variety of zinc finger proteins and a group of poxvirus proteins and which mediates <corefTheme idref1="T57">protein</corefTheme>-<corefTheme idref1="T58">protein</corefTheme> <clueType>interactions</clueType>.</clue>
</event>
<event KT="Fact" id="E65">
<type class="Positive_regulation"/>
<theme idref="E64"/>
<cause idref="T75"/>
<clue>The PLZF-RAR alpha fusion protein contains an approximately 120-amino-acid N-terminal motif (called the POZ domain), which is also found in a variety of zinc finger proteins and a group of poxvirus proteins and which <clueType>mediates</clueType> protein-protein interactions.</clue>
</event>
<sentence id="S8">Deletion of the <term id="T79" lex="PLZF_POZ_domain" sem="Protein_domain_or_region">PLZF <term id="T80" lex="POZ_domain" sem="Protein_domain_or_region">POZ domain</term></term> partially abrogated the inhibitory effect of <term id="T81" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term> on <term id="T82" lex="RA-induced_differentiation" sem="Other"><term id="A18" sem="Organic_compound_other">RA</term>-induced <term id="A19" sem="Other">differentiation</term></term> and on <term id="T83" lex="RA-mediated_type_II_TGase_up-regulation" sem="Other"><term id="A20" sem="Organic_compound_other">RA</term>-mediated <term id="T84" lex="type_II_TGase" sem="Protein_family_or_group">type II TGase</term> up-regulation</term>, suggesting that <term id="T85" lex="POZ-mediated_protein_interaction" sem="Other"><term id="A21" sem="Protein_domain_or_region">POZ</term>-mediated protein interactions</term> might be responsible for the inhibitory transcriptional activities of <term id="T86" lex="PLZF-RAR_alpha" sem="Protein_molecule">PLZF-RAR alpha</term>.</sentence>
<event KT="Method" id="E66">
<type class="Mutagenesis"/>
<theme idref="T79"/>
<clue><clueType>Deletion</clueType> <linkTheme>of</linkTheme> the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
<comment>ARTIFICIAL</comment></event>
<event id="E67">
<type class="Positive_regulation"/>
<theme idref="A19"/>
<cause idref="A18"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-<clueType>induced</clueType> differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E68">
<type class="Positive_regulation"/>
<theme idref="T84"/>
<cause idref="A20"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-<linkCause>mediated</linkCause> type II TGase <clueType>up-regulation</clueType>, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E69">
<type class="Negative_regulation"/>
<theme idref="E67"/>
<cause idref="T81"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the <clueType>inhibitory effect</clueType> <linkCause>of</linkCause> PLZF-RAR alpha <linkTheme>on</linkTheme> RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E70">
<type class="Negative_regulation"/>
<theme idref="E68"/>
<cause idref="T81"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the <clueType>inhibitory effect</clueType> <linkCause>of</linkCause> PLZF-RAR alpha on RA-induced differentiation and <linkTheme>on</linkTheme> RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event KT="Other" id="E71">
<type class="Positive_regulation"/>
<theme idref="E64"/>
<cause idref="A21"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-<clueType>mediated</clueType> <corefTheme>protein interactions</corefTheme> might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event KT="Other" id="E72">
<type class="Negative_regulation"/>
<cause idref="T86"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the <clueType>inhibitory transcriptional activities</clueType> <linkCause>of</linkCause> PLZF-RAR alpha.</clue>
<comment>NO THEME</comment></event>
<event CL="L1" KT="Analysis" id="E73" uncertainty="probable">
<type class="Regulation"/>
<theme idref="E72"/>
<cause idref="E71"/>
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, <clueKT>suggesting</clueKT> that POZ-mediated protein interactions <clueCL>might</clueCL> be <clueType>responsible</clueType> <linkTheme>for</linkTheme> the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
